Compare SANM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANM | BLCO |
|---|---|---|
| Founded | 1980 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electrical Products | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.0B |
| IPO Year | 1993 | 2022 |
| Metric | SANM | BLCO |
|---|---|---|
| Price | $176.78 | $17.39 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 14 |
| Target Price | ★ $120.00 | $17.31 |
| AVG Volume (30 Days) | ★ 625.8K | 413.8K |
| Earning Date | 01-26-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.07 | N/A |
| EPS | ★ 4.46 | N/A |
| Revenue | ★ $8,128,382,000.00 | $4,976,000,000.00 |
| Revenue This Year | $75.74 | $8.08 |
| Revenue Next Year | $12.92 | $5.77 |
| P/E Ratio | $39.60 | ★ N/A |
| Revenue Growth | ★ 7.40 | 6.23 |
| 52 Week Low | $63.67 | $10.45 |
| 52 Week High | $178.39 | $20.71 |
| Indicator | SANM | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 68.85 | 66.31 |
| Support Level | $157.25 | $16.39 |
| Resistance Level | $167.06 | $17.35 |
| Average True Range (ATR) | 6.95 | 0.48 |
| MACD | 1.15 | 0.08 |
| Stochastic Oscillator | 99.42 | 88.63 |
Sanmina Corp is a provider of integrated manufacturing solutions, components, and after-market services to original equipment manufacturers in the communications networks, storage, industrial, defense and aerospace end markets. The operations are managed as two businesses: Integrated Manufacturing Solutions, which consists of printed circuit board assembly and represents a majority of the firm's revenue; and Components, Products, and Services, which includes interconnect systems and mechanical systems. The firm generates revenue primarily in the United States, China, and Mexico, but has a presence around the world.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.